Stop and Screen

PUBLISHED ON November 25, 2020

HealthcareNOW Radio (November 23, 2020) My father was 39 when he died of lung cancer, attributed to his twenty-year Lucky Strikes habit. The U.S. Surgeon General had yet to issue his first report on the health hazards of smoking in 1960 when my father was diagnosed.

read more

bioAffinity Technologies to Present at 2020 American Society of Cell Biology Meeting

PUBLISHED ON November 10, 2020

Nov. 10, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that its poster “Meso-tetra (4-carboxyphenyl) porphyrin (TCPP) is incorporated into cancer cells by the CD320 receptor and clathrin mediated endocytosis” will be presented during the session Cancer Therapy: Defining Therapeutic Targets and New Therapeutics at the American Society of Cell Biology’s Cell Bio Virtual 2020 - An Online ASCB|EMBO Meeting Dec. 2-16, 2020.

read more

bioAffinity Technologies to Present Poster at World Conference on Lung Cancer 2020

PUBLISHED ON October 22, 2020

OCTOBER 22, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, announced its poster “Automated Flow Cytometry Test Distinguishes Cancer from Non-Cancer in Sputum with High Sensitivity and Specificity” has been accepted for presentation at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, Singapore, Worldwide Virtual Event (WCLC 2020) from Jan. 28 to 31, 2021.

read more

Smiths Medical and bioAffinity Technologies Partner to Advance Non-Invasive Testing for Early Lung Cancer

PUBLISHED ON October 15, 2020

OCTOBER 15, 2020 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, and Smiths Medical, a leading global medical device manufacturer, today announced a partnership to improve patient care with at-home collection of sputum to be analyzed by CyPath® Lung, a non-invasive flow cytometry diagnostic test for lung cancer that is being developed as a Laboratory Developed Test (LDT) by Precision Pathology Services.

read more

bioAffinity Technologies was selected as one of San Antonio’s Top 2020 Innovators. In this video, you will see Maria Zannes, President and Chief Executive Officer, speak about what drives motivation, innovation and success and kick off San Antonio’s premier annual event celebrating the City’s healthcare and bioscience industry.

 

www.thehealthcell.org/sitepage/state-of-the-industry/